

## **STORM Therapeutics appoints Dr John Haurum on Board**

27 June 2019 | News

**Dr Haurum has over 20 years' experience in the international biotech industry**



STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics has announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.

Dr Haurum has over 20 years' experience in the international biotech industry. Previously John was Chief Executive Officer of F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies, with multiple strategic collaborations with AbbVie, Merck KGaA, Denali and Boehringer Ingelheim.

Prior to F-star, Dr Haurum was VP Research at ImClone Systems, and was previously CSO and Co-Founder of Symphogen. He is currently Executive Chairman of the Board at Synklino, Chairman of the Board of Agomab and is on the board of NeoPhore and Synact Pharma ApS. Dr Haurum has a Medical Degree and MSc in Immunology from AarhusUniversity, and a DPhil in Immunology from the University of Oxford.